Citigroup Cuts Krystal Biotech (NASDAQ:KRYS) Price Target to $155.00

Krystal Biotech (NASDAQ:KRYS) had its target price trimmed by Citigroup from $215.00 to $155.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other equities research analysts have also weighed in on KRYS. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. Guggenheim dropped their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Chardan Capital restated a “buy” rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. HC Wainwright restated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $211.13.

Krystal Biotech Stock Up 0.2%

Krystal Biotech stock opened at $130.60 on Friday. Krystal Biotech has a 52-week low of $127.40 and a 52-week high of $219.34. The firm has a fifty day moving average of $166.74 and a 200-day moving average of $168.54. The firm has a market capitalization of $3.77 billion, a P/E ratio of 43.68 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). The firm had revenue of $88.18 million during the quarter, compared to analysts’ expectations of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. On average, research analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This trade represents a 1.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently added to or reduced their stakes in KRYS. Brooklyn Investment Group boosted its stake in shares of Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock worth $25,000 after buying an additional 105 shares during the last quarter. Twin Tree Management LP acquired a new position in shares of Krystal Biotech during the 1st quarter worth about $29,000. Fifth Third Bancorp boosted its stake in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after buying an additional 105 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock worth $58,000 after buying an additional 177 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Krystal Biotech during the 1st quarter worth about $74,000. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).